Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Purple Biotech American Depositary Shares Representing 200 Ord Shs PPBT

Healthcare
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi... see more

Recent & Breaking News (NDAQ:PPBT)

Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study

GlobeNewswire March 16, 2023

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

GlobeNewswire February 14, 2023

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

GlobeNewswire February 8, 2023

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer

GlobeNewswire February 2, 2023

Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments

GlobeNewswire January 3, 2023

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

GlobeNewswire November 15, 2022

Purple Biotech to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 10, 2022

Purple Biotech Reports Third Quarter 2022 Financial Results

GlobeNewswire November 8, 2022

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

GlobeNewswire November 2, 2022

Purple Biotech Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Purple Biotech Announces Executive Leadership Changes

GlobeNewswire July 14, 2022

Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile

GlobeNewswire May 27, 2022

Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients

GlobeNewswire May 18, 2022

Purple Biotech Reports First Quarter 2022 Financial Results

GlobeNewswire May 12, 2022

Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting

GlobeNewswire April 11, 2022

Purple Biotech Reports Second Half and Full-Year 2021 Financial Results

GlobeNewswire February 9, 2022

Purple Biotech Issues Letter to Shareholders

GlobeNewswire February 4, 2022

Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors

GlobeNewswire January 6, 2022

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

GlobeNewswire December 9, 2021

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program

GlobeNewswire December 6, 2021